GLP-1 receptor agonist medications including semaglutide and tirzepatide have demonstrated remarkable efficacy for weight loss in clinical trials, with some patients losing 15 to 22 percent of body weight. Beyond weight loss, these drugs have shown benefits for cardiovascular outcomes, sleep apnea, and kidney disease in large randomized trials, broadening their potential application well beyond obesity treatment.
However, the drugs come with significant caveats. Most patients who discontinue GLP-1 medications regain substantial weight within a year, suggesting the drugs treat obesity as a chronic condition requiring indefinite treatment rather than providing a lasting cure. Side effects including nausea, vomiting, and rare but serious pancreatitis risks affect a meaningful minority of patients. Access remains severely limited by cost, with monthly prices exceeding 1,000 dollars without insurance coverage.
